Literature DB >> 22624723

A comparative quality assessment of evidence-based clinical guidelines in endocrinology.

Jonathan M Hazlehurst1, Matthew J Armstrong, Mark Sherlock, Ian A Rowe, Michael W O'Reilly, Jayne A Franklyn, Paul M Stewart, Jeremy W Tomlinson.   

Abstract

CONTEXT: Evidence-based clinical guidelines in endocrinology attempt to improve and standardize patient care. There has been an expansion in guideline production although some of the heterogeneous methods used to assess the quality of the underlying evidence base might limit interpretation and implementation.
DESIGN: Current and archived guidelines from major endocrine organizations were accessed. The organizations used six different methods to rate underlying evidence, including Grading of Recommendations Assessment, Development and Evaluation (GRADE). To allow direct comparison between guidelines produced by different organizations, the levels of evidence used to generate them were graded according to the standardized system: 'high' based on randomized, controlled trials and meta-analyses, 'moderate' based on nonrandomized studies and 'low' based on expert opinion.
RESULTS: There was an increase in guideline production over time (1995-2000 = 9, 2001-2005 = 12, 2006-2011 = 36). Three guidelines were updated with an average delay of 4·3 years and an increase in recommendations per guideline (21·1%). Encouragingly, whilst updates had similar levels of 'high'-quality evidence, there was increased reliance on 'moderate'-category evidence and less on 'low''-quality evidence' ('high', 6·3% vs 6·5%; 'moderate', 46·1% vs 59·1%; 'low', 47·7% vs 34·4%). A high proportion of 'low'-category evidence was seen throughout all organizations. Rarer conditions and recommendations concerning treatment efficacy were particularly reliant on 'low'-category evidence.
CONCLUSIONS: The level of evidence underpinning current guidelines highlights areas in need of well-designed, collaborative clinical research. Furthermore, criteria to define when guideline updates are necessary are currently lacking. A standardized method of assessment, such as GRADE, would promote understanding and compliance by guideline users with the ultimate aim of enhancing patient care.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 22624723     DOI: 10.1111/j.1365-2265.2012.04441.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Critical appraisal and systematic review of guidelines for perioperative diabetes management: 2011-2017.

Authors:  Xiaoyang Song; Jinjing Wang; Yuting Gao; Yang Yu; Jingyi Zhang; Qi Wang; Xiaoting Ma; Janne Estille; Xinye Jin; Yaolong Chen; Yiming Mu
Journal:  Endocrine       Date:  2018-11-16       Impact factor: 3.633

2.  Importance and Presence of High-Quality Evidence for Clinical Decisions in Neurosurgery: International Survey of Neurosurgeons.

Authors:  Jill Martens; Guido de Jong; Maroeska Rovers; Gert Westert; Ronald Bartels
Journal:  Interact J Med Res       Date:  2018-10-12

3.  Polypharmacy and Pharmacological Treatment of Diabetes in Older Individuals: A Population-Based Study in Quebec, Canada.

Authors:  Marie-Eve Gagnon; Caroline Sirois; Marc Simard; Céline Plante
Journal:  Pharmacy (Basel)       Date:  2019-12-01

4.  Development of a Patient Decision Aid on the Choice of Diabetes Medication for Filipino Patients with Type 2 Diabetes Mellitus.

Authors:  Anna Angelica Macalalad-Josue; Lia Aileen Palileo-Villanueva; Mark Anthony Sandoval; Jose Paolo Panuda
Journal:  J ASEAN Fed Endocr Soc       Date:  2019-04-04

5.  Is the endocrine research pipeline broken? A systematic evaluation of the Endocrine Society clinical practice guidelines and trial registration.

Authors:  Naykky Singh Ospina; Rene Rodriguez-Gutierrez; Juan P Brito; William F Young; Victor M Montori
Journal:  BMC Med       Date:  2015-08-12       Impact factor: 8.775

6.  Better prioritization to increase research value and decrease waste.

Authors:  Agnes Dechartres; Philippe Ravaud
Journal:  BMC Med       Date:  2015-09-29       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.